Special biological issues in the management of women with schizophrenia

Expert Review of Neurotherapeutics

Volumn 12, Issue 7, 2012, Pages 823-833

  Kulkarni, Jayashri ^a   Gavrilidis, Emmy ^a   Hayes, Emily ^a   Heaton, Victoria ^a   Worsley, Roisin ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

estrogen; hormones; psychosis; schizophrenia; sex hormones

Indexed keywords

ALLOPGRENANOLONE; CLOZAPINE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OXYTOCIN; PRASTERONE; PRASTERONE SULFATE; PREGNENOLONE; PREGNENOLONE SULFATE; RALOXIFENE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; AGE DISTRIBUTION; CLINICAL FEATURE; COGNITION; DISEASE COURSE; DRUG BLOOD LEVEL; FEMALE GENITAL SYSTEM; HORMONE ACTION; HUMAN; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; SOCIAL BEHAVIOR; UNSPECIFIED SIDE EFFECT; WOMEN'S HEALTH;

ESTRADIOL; ESTROGENS; FEMALE; HUMANS; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 84864627434     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.62     Document Type: Review

References (134)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th Edition TR (DSM-IV-TR). American Psychiatric Association, DC, USA (2000).
2. Riecher-Rössler A, Kulkarni J. Estrogens and gonadal function in schizophrenia and related psychoses. Curr. Top. Behav. Neurosci. 8, 155-171 (2011).
3. Kraepelin E. Dementia praecox and paraphrenia. In: Psychiatrie: Ein Lehrbuch fur Studierende und Artze. JA Barth, Leipzig, Germany (1893).
4. Markham JA. Sex steroids and schizophrenia. Rev. Endocr. Metab. Disord doi:10.1007/s11154-011-9184-2 (2011) (Epub ahead of print).
5. Perälä J, Suvisaari J, Saarni SI et al Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 64(1), 19-28 (2007).
6. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 30, 67-76 (2008).
7. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch. Gen. Psychiatry 60(6), 565-571 (2003).
8. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the infuence of sex, urbanicity, migrant status and methodology. BMC Med. 2, 13 (2004).
9. McGrath JJ. The surprisingly rich contours of schizophrenia epidemiology. Arch. Gen. Psychiatry 64(1), 14-16 (2007).
10. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 28(Suppl. 2), 17-54 (2003).
11. Seeman M V. The role of estrogen in schizophrenia. J. Psychiatry Neurosci. 21(2), 123-127 (1996).
12. DeLisi LE. The signifcance of age of onset for schizophrenia. Schizophr. Bull. 18 (2), 209-215 (1992).
13. Drake RJ, Addington J, Viswanathan A, Lewis SW, Abel KM. How do age and gender interact as determinants of the incidence and course of non-affective psychosis? Acta Psychiatr. Scand. (2012) (In Press).
14. Häfner H, Nowotny B, Löffer W, an der Heiden W, Maurer K. When and how does schizophrenia produce social defcits? Eur. Arch. Psychiatry Clin. Neurosci. 246(1), 17-28 (1995).
15. Häfner H, Löffer W, Maurer K, Hambrecht M, an der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr. Scand. 100(2), 105-118 (1999).
16. Cotton SM, Lambert M, Schimmelmann BG et al. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with frst episode psychosis. Schizophr. Res. 114 (1-3), 17-24 (2009).
17. Castle DJ, Wessely S, Murray RM. Sex and schizophrenia: effects of diagnostic stringency, and associations with and premorbid variables. Br. J. Psychiatry 162, 658-664 (1993).
18. Goldstein JM, Link BG. Gender and the expression of schizophrenia. J. Psychiatr. Res. 22(2), 141-155 (1988).
19. Morgan VA, Castle DJ, Jablensky AV. Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian National Study of Low Prevalence (Psychotic) Disorders. Aust. NZ J. Psychiatry 42(1), 74-82 (2008).
20. Opjordsmoen S. Long-term clinical outcome of schizophrenia with special reference to gender differences. Acta Psychiatr. Scand. 83(4), 307-313 (1991).
21. Riecher-Rössler A, Seeman MV. Oestrogens and schizophrenia- introduction. Arch. Womens. Ment. Health 5(3), 91-92 (2002).
22. Boyce P, Barriball E. Puerperal psychosis. Arch. Womens. Ment. Health 13(1), 45-47 (2010).
23. Riecher-Rössler A. Oestrogen effects in schizophrenia and their potential therapeutic implications-review. Arch. Womens. Ment. Health 5(3), 111-118 (2002).
24. Krafft-Ebing G. Untersuchungen uber Irresein zur Zeit der Menstruation: ein klinischer Beitrag zur Lehre vom periodischen Irresein. Arch. Gen. Psychiatry 8, 65-107 (1896).
25. Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol. Med. 37(10), 1427-1436 (2007).
26. Choi SH, Kang SB, Joe SH. Changes in premenstrual symptoms in women with schizophrenia: a prospective study. Psychosom. Med. 63(5), 822-829 (2001).
27. Ko YH, Joe SH, Cho W et al. Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology 53(4), 169-175 (2006).
28. Rubin LH, Carter CS, Drogos L, Pournajaf-Nazarloo H, Sweeney JA, Maki PM. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res. 124(1-3), 13-21 (2010).
29. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr. Bull. 20(1), 203-214 (1994).
30. Fink G, Sumner BE, Rosie R, Grace O, Quinn JP. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell. Mol. Neurobiol 16(3), 325-344 (1996).
31. Hughes ZA, Liu F, Marquis K et al Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr. Mol. Pharmacol. 2(3), 215-236 (2009).
32. ter Horst GJ. Estrogen in the limbic system. Vitam. Horm. 82, 319-338 (2010).
33. McEwen B. Estrogen actions throughout the brain. Recent Prog. Horm. Res. 5 7, 357-384 (2002).
34. Prossnitz ER, Arterburn JB, Sklar LA. GPR30: a G protein-coupled receptor for estrogen. Mol. Cell. Endocrinol. 265-266, 138-142 (2007).
35. Cosimo Melcangi R, Garcia-Segura LM. Sex-specifc therapeutic strategies based on neuroactive steroids: in search for innovative tools for neuroprotection. Horm. Behav. 57(1), 2-11 (2010).
36. McEwen BS. Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms. J. Appl. Physiol. 91(6), 2785-2801 (2001).
37. Ciocca DR, Roig LM. Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr. Rev. 16(1), 35-62 (1995).
38. Iritani S. Neuropathology of schizophrenia: a mini review. Neuropathology 27(6), 604-608 (2007).
39. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI fndings in schizophrenia. Schizophr. Res. 49(1-2), 1-52 (2001).
40. Andreasen NC, Pierson R. The role of the cerebellum in schizophrenia. Biol. Psychiatry 64(2), 81-88 (2008).
41. Fornito A, Yucel M, Pantelis C. Reconciling neuroimaging and neuropathological fndings in schizophrenia and bipolar disorder. Curr. Opin. Psychiatry 22(3), 312-319 (2009).
42. Flashman LA, Green MF. Review of cognition and brain structure in schizophrenia: profles, longitudinal course, and effects of treatment. Psychiatr. Clin. North Am. 27(1), 1-18, vii (2004).
43. Arevalo MA, Santos-Galindo M, Bellini MJ, Azcoitia I, Garcia-Segura LM. Actions of estrogens on glial cells: implications for neuroprotection. Biochim. Biophys. Acta 1800 (10), 1106-1112 (2010).
44. Behl C. Estrogen can protect neurons: modes of action. J. Steroid Biochem. Mol. Biol. 83 (1-5), 195-197 (2003).
45. Bryant DN, Dorsa DM. Roles of estrogen receptors alpha and beta in sexually dimorphic neuroprotection against glutamate toxicity. Neuroscience 170 (4), 1261-1269 (2010).
46. Rao ML, Kölsch H. Effects of estrogen on brain development and neuroprotection-implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 28(Suppl. 2), 83-96 (2003).
47. Bishop J, Simpkins JW. Role of estrogens in peripheral and cerebral glucose utilization. Rev. Neurosci. 3(2), 121-138 (1992).
48. Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog. Neurobiol. 63(1), 29-60 (2001).
49. Li J, Siegel M, Yuan M et al. Estrogen enhances neurogenesis and behavioral recovery after stroke. J. Cereb. Blood Flow Metab. 31(2), 413-425 (2011).
50. Liu M, Kelley MH, Herson PS, Hurn PD. Neuroprotection of sex steroids. Minerva Endocrinol. 35(2), 127-143 (2010).
51. Yang LC, Zhang QG, Zhou CF et al Extranuclear estrogen receptors mediate the neuroprotective effects of estrogen in the rat hippocampus. PLoS ONE 5(5), e9851 (2010).
52. Matsumoto A. Synaptogenic action of sex steroids in developing and adult neuroendocrine brain. Psychoneuroendocrinology 16(1-3), 25-40 (1991).
53. Elzer JG, Muhammad S, Wintermantel TM et al. Neuronal estrogen receptor-alpha mediates neuroprotection by 17beta-estradiol. J. Cereb. Blood Flow Metab 30(5), 935-942 (2010).
54. Simpkins JW, Yi KD, Yang SH, Dykens JA. Mitochondrial mechanisms of estrogen neuroprotection. Biochim. Biophys. Acta 1800(10), 1113-1120 (2010).
55. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res. 34(6), 1021-1029 (2009).
56. Morris JA, Jordan CL, Breedlove SM. Sexual differentiation of the vertebrate nervous system. Nat. Neurosci. 7(10), 1034-1039 (2004).
57. Schulz KM, Molenda-Figueira HA, Sisk CL. Back to the future: the organizational-activational hypothesis adapted to puberty and adolescence. Horm. Behav. 55(5), 597-604 (2009).
58. González-Maeso J, Ang RL, Yuen T et al Identifcation of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452(7183), 93-97 (2008).
59. Horacek J, Bubenikova-Valesova V, Kopecek M et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20(5), 389-409 (2006).
60. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog. Brain Res. 172, 199-212 (2008).
61. Sánchez MG, Bourque M, Morissette M, Di Paolo T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16(3), e43-e71 (2010).
62. Di Paolo T, Falardeau P. Modulation of brain and pituitary dopamine receptors by estrogens and prolactin. Prog Neuropsychopharmacol. Biol. Psychiatry 9(5-6), 473-480 (1985).
63. Chavez C, Hollaus M, Scarr E, Pavey G, Gogos A, van den Buuse M. The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res. 1321, 51-59 (2010).
64. Lokuge S, Frey BN, Foster JA, Soares CN, Steiner M. The rapid effects of estrogen: a mini-review. Behav. Pharmacol. 21(5-6), 465-472 (2010).
65. Bethea CL, Mirkes SJ, Shively CA, Adams MR. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol. Psychiatry 47(6), 562-576 (2000).
66. Gundlah C, Lu NZ, Bethea CL. Ovarian steroid regulation of monoamine oxidase-A and-B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology 160(3), 271-282 (2002).
67. Smith LJ, Henderson JA, Abell CW, Bethea CL. Effects of ovarian steroids and raloxifene on proteins that synthesize transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology 29(11), 2035-2045 (2004).
68. Osterlund MK, Halldin C, Hurd YL. Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A) receptor mRNA and binding levels in the rat brain. Synapse 35(1), 39-44 (2000).
69. Moses EL, Drevets WC, Smith G et al Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiatry 48(8), 854-860 (2000).
70. Adams MM, Fink SE, Janssen WG, Shah RA, Morrison JH. Estrogen modulates synaptic N-methyl-D-aspartate receptor subunit distribution in the aged hippocampus. J. Comp. Neurol. 474(3), 419-426 (2004).
71. Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci. Biobehav. Rev. 32(5), 1014-1023 (2008).
72. Goff DC, Coyle JT The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158(9), 1367-1377 (2001).
73. Häfner H, Behrens S, De Vry J, Gattaz WF. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur. Arch. Psychiatry Clin. Neurosci. 241(1), 65-68 (1991).
74. Gogos A, Kwek P, van den Buuse M. The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia. Psychopharmacology 219(1), 213-224 (2012).
75. 1A, 5-HT, or 5-HT receptors. J. Pharmacol Exp. Ther. 333(1), 218-227 (2010).
76. Arad M, Weiner I. Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis? Neuropsychopharmacology 35(7), 1570-1582 (2010).
77. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 20(3), 247-252 (1996).
78. Kulkarni J, Riedel A, de Castella AR et al. Estrogen-a potential treatment for schizophrenia. Schizophr. Res. 48(1), 137-144 (2001).
79. Kulkarni J, de Castella A, Fitzgerald PB et al. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 65(8), 955-960 (2008).
80. Akhondzadeh S, Nejatisafa AA, Amini H et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(6), 1007-1012 (2003).
81. Bergemann N, Parzer P, Jaggy S, Auler B, Mundt C, Maier-Braunleder S. Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial. Schizophr. Bull. 34(6), 1172-1181 (2008).
82. Ko Y-H, Joe S-H, Cho W et al. Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia. Int. J. Psychiatry Clin. Pract. 10(2), 97-104 (2006).
83. Usall J, Huerta-Ramos E, Iniesta R et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry 72(11), 1552-1557 (2011).
84. Kulkarni J, Gurvich C, Lee SJ et al. Piloting the effective therapeutic dose of adjunctive selective estrogen-receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 35(8), 1142-1147 (2010).
85. Good KP, Kopala LC, Martzke JS et al Hormone replacement therapy in postmenopausal women with schizophrenia: preliminary fndings. Schizophr. Res. 12(3), 131 (1999).
86. Chua WL, de Izquierdo SA, Kulkarni J, Mortimer A. Estrogen for schizophrenia. Cochrane Database Syst. Rev. 4, CD004719 (2005).
87. Mortimer AM. Relationship between estrogen and schizophrenia. Expert Rev. Neurother. 7(1), 45-55 (2007).
88. Bergemann N, Mundt C, Parzer P et al Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr. Res. 74(2-3), 125-134 (2005).
89. Louzã MR, Marques AP, Elkis H, Bassitt D, Diegoli M, Gattaz WF. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr. Res. 66(2-3), 97-100 (2004).
90. Glazer WM, Naftolin F, Morgenstern H, Barnea ER, MacLusky NJ, Brenner LM. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology 10(3), 345-350 (1985).
91. Melcangi RC, Panzica G, Garcia-Segura LM. Neuroactive steroids: focus on human brain. Neuroscience 191, 1-5 (2011).
92. Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front. Neuroendocrinol. 30(1), 65-91 (2009).
93. Ritsner MS. The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia. Neuroscience 191, 91-100 (2011).
94. Marx CE, Bradford DW, Hamer RM et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 191, 78-90 (2011).
95. Feifel D, Macdonald K, Nguyen A et al Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 68(7), 678-680 (2010).
96. Dennis CL, Ross LE, Herxheimer A Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst. Rev. 4, CD001690 (2008).
97. Kretschmer E. Korperbau und Charakter. Untersuchungen zum Konstitutionsproblem und zur Lehre von den Temperamenten. Springer, Berlin, Germany (1921).
98. Maric N, Popovic V, Jasovic-Gasic M, Pilipovic N, van Os J. Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in frst-episode psychosis. Schizophr. Res. 73(2-3), 351-355 (2005).
99. Bergemann N, Mundt C, Parzer P et al. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr. Res. 73(2-3), 357-366 (2005).
100. Canuso CM, Goldstein JM, Wojcik J et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 111(1), 11-20 (2002).
101. Huber TJ, Rollnik J, Wilhelms J, von zur Muhlen A, Emrich HM, Schneider U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 26(1), 27-35 (2001).
102. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 150(6), 1115-1121 (2005).
103. Archer DF. Premature menopause increases cardiovascular risk. Climacteric 12(Suppl. 1), 26-31 (2009).
104. O'Donnell E, Goodman JM, Harvey PJ. Clinical review: cardiovascular consequences of ovarian disruption: a focus on functional hypothalamic amenorrhea in physically active women. J. Clin. Endocrinol. Metab 96(12), 3638-3648 (2011).
105. Cauley JA, Robbins J, Chen Z et al.; Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290(13), 1729-1738 (2003).
106. Baker L, Meldrum KK, Wang M et al. The role of estrogen in cardiovascular disease. J. Surg. Res. 115(2), 325-344 (2003).
107. Chlebowski RT, Hendrix SL, Langer RD et al.; WHI Investigators. Infuence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289(24), 3243-3253 (2003).
108. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 82(5), 410-417 (2010).
109. Soares CN, Poitras JR, Prouty J. Effect of reproductive hormones and selective estrogen-receptor modulators on mood during menopause. Drugs Aging 20 (2), 85-100 (2003).
110. Rossouw JE, Anderson GL, Prentice RL et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefts of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002).
111. Beral V Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382), 419-427 (2003).
112. Arevalo MA, Santos-Galindo M, Lagunas N, Azcoitia I, Garcia-Segura LM. Selective estrogen-receptor modulators as brain therapeutic agents. J. Mol. Endocrinol. 46(1), R1-R9 (2011).
113. DonCarlos LL, Azcoitia I, Garcia-Segura LM. Neuroprotective actions of selective estrogen-receptor modulators. Psychoneuroendocrinology 34(Suppl. 1), S113-S122 (2009).
114. Littleton-Kearney MT, Ostrowski NL, Cox DA, Rossberg MI, Hurn PD. Selective estrogen-receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev. 8(3), 309-330 (2002).
115. Cyr M, Calon F, Morissette M, Grandbois M, Di Paolo T, Callier S. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr. Pharm. Des. 6(12), 1287-1312 (2000).
116. Cyr M, Thibault C, Morissette M, Landry M, Di Paolo T. Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain. Neuropsychopharmacology 25(2), 242-257 (2001).
117. Landry M, Lévesque D, Di Paolo T. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 76(4), 214-222 (2002).
118. Bryant HU. Selective estrogen-receptor modulators. Rev. Endocr. Metab. Disord. 3(3), 231-241 (2002).
119. Thompson KN, Kulkarni J, Sergejew AA. Extrapyramidal symptoms and oestrogen. Acta Psychiatr. Scand. 101(2), 130-134 (2000).
120. Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J. Clin. Psychopharmacol. 22(2), 109-114 (2002).
121. Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br. J. Clin. Pharmacol. 51(4), 317-324 (2001).
122. Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 28(Suppl. 2), 97-108 (2003).
123. Tworoger SS, Hankinson SE. Prolactin and breast cancer etiology: an epidemiologic perspective. J. Mammary Gland Biol. Neoplasia 13(1), 41-53 (2008).
124. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology 28(Suppl. 2), 1-16 (2003).
125. Kulkarni J. Special issues in managing long-term mental illness in women. Int. Rev. Psychiatry 22(2), 183-190 (2010).
126. Bushe CJ, Bradley AJ, Wildgust HJ, Hodgson RE. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophr. Res. 114(1-3), 6-16 (2009).
127. McEvoy JP, Meyer JM, Goff DC et al Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80(1), 19-32 (2005).
128. Haack S, Seeringer A, Thurmann PA, Becker T, Kirchheiner J. Sex-specifc differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics 10(9), 1511-1526 (2009).
129. Blin O, Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. J. Clin. Psychiatry 62(Suppl. 7), 11-21 (2001).
130. Collins P, Mosca L, Geiger MJ et al. Effects of the selective estrogen-receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 119(7), 922-930 (2009).
131. Pollock BG. Gender differences in psychotropic drug metabolism. Psychopharmacol. Bull. 33(2), 235-241 (1997).
132. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J. Clin. Psychiatry 65(7), 932-939 (2004).
133. Arad M, Weiner I. Sex-dependent antipsychotic capacity of 17ß-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males. Neuropsychopharmacology 35(11), 2179-2192 (2010).
134. Kulkarni J, de Castella A, Headey B et al Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr. Res. 125(2-3), 278-283 (2011).